Durvalumab Combined With Chemotherapy Neoadjuvant Therapy of Biliary Tract Cancer

NCT05640791 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Resectable Biliary Tract Cancer

Interventions

DRUG: Cisplatin
DRUG: Gemcitabine
DRUG: Nab-paclitaxel
DRUG: Durvalumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital